NCT04797767 2026-04-17
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT05849662 2026-04-15
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Recruiting
NCT06561152 2026-04-14
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
Phase 1/2 Recruiting
NCT04049539 2026-04-08
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04663347 2026-04-08
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT03793478 2026-04-01
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo
Phase 1/2 Active not recruiting
NCT03214562 2026-03-05
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07451912 2026-03-05
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
The First Affiliated Hospital of Soochow University
Phase 1/2 Recruiting
NCT07053020 2026-03-04
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting